<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048225</url>
  </required_header>
  <id_info>
    <org_study_id>602-04/21-08/07</org_study_id>
    <nct_id>NCT05048225</nct_id>
  </id_info>
  <brief_title>Dietary Salt During Pregnancy and Maternal Vascular Function</brief_title>
  <official_title>Influence of Dietary Salt Intake During Pregnancy on Maternal Systemic and Uteroplacental Vascular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Josip Juraj Strossmayer University of Osijek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Josip Juraj Strossmayer University of Osijek</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to investigate the association of dietary salt intake during&#xD;
      pregnancy with systemic micro- and macrovascular reactivity and uteroplacental vascular&#xD;
      function of the mother, and to examine the potential impact of elevated oxidative stress on&#xD;
      this association. Also, the aim is to investigate whether there is an association between&#xD;
      excessive salt intake during pregnancy and the outcome of pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the study pregnant women at the third trimester of pregnancy (37-38 weeks of&#xD;
      pregnancy) will have one study visit during which following procedures will be done:&#xD;
&#xD;
        -  measurement of maternal systemic microvascular function by Laser Doppler flowmetry&#xD;
           (post-occlusive reactive hyperemia, iontophoresis of acetylcholine and sodium&#xD;
           nitroprusside)&#xD;
&#xD;
        -  measurement of maternal systemic macrovascular function by vascular ultrasound&#xD;
           measurement of brachial artery flow mediated dilation (FMD)&#xD;
&#xD;
        -  measurement of maternal uteroplacental function by ultrasound color Doppler measurement&#xD;
           of umbilical artery and fetal middle cerebral artery blood flow&#xD;
&#xD;
        -  venous blood sampling; serum will be stored for measurement of oxidative stress, matrix&#xD;
           metalloproteinase 9 and endocan level&#xD;
&#xD;
        -  24-hour urine natriuresis (to estimate daily salt intake)&#xD;
&#xD;
        -  measurement of blood pressure, heart rate, height and weight, body composition&#xD;
&#xD;
      Immediately after the childbirth following procedures will be done:&#xD;
&#xD;
        -  assessment of pregnancy outcome (duration of pregnancy, child birth weight, child birth&#xD;
           length and Apgar score)&#xD;
&#xD;
        -  placental tissue will be taken and stored for measurement of matrix metalloproteinase 9&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal systemic microvascular function</measure>
    <time_frame>at one time point in the third trimester of pregnancy (37-38 weeks of pregnancy)</time_frame>
    <description>Skin microvascular reactivity assessed by Laser Doppler flowmetry (post-occlusive reactive hyperemia, iontophoresis of acetylcholine and sodium nitroprusside) - measured in perfusion units (PU)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal systemic macrovascular function</measure>
    <time_frame>at one time point in the third trimester of pregnancy (37-38 weeks of pregnancy)</time_frame>
    <description>Vascular ultrasound measurement of brachial artery flow mediated dilation (FMD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal uteroplacental function</measure>
    <time_frame>at one time point in the third trimester of pregnancy (37-38 weeks of pregnancy)</time_frame>
    <description>Ultrasound color Doppler measurement of umbilical artery and fetal middle cerebral artery blood flow</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress - thiobarbituric acid reactive substances (TBARS)</measure>
    <time_frame>at one time point in the third trimester of pregnancy (37-38 weeks of pregnancy)</time_frame>
    <description>Measurement of biomarkers of oxidative stress level. Thiobarbituric acid reactive substances (TBARS) - biomarker of lipid peroxidation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matrix metalloproteinase 9</measure>
    <time_frame>at one time point in the third trimester of pregnancy (37-38 weeks of pregnancy) (serum) and immediately after childbirth (placental tissue sample)</time_frame>
    <description>ELISA measurement of serum matrix metalloproteinase 9 level in mother serum and placental tissue sample (taken after childbirth)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocan</measure>
    <time_frame>at one time point in the third trimester of pregnancy (37-38 weeks of pregnancy)</time_frame>
    <description>ELISA measurement of serum endocan level - proteoglycan associated with endothelium activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome - duration</measure>
    <time_frame>the outcome measure will be assessed at one time point in the third trimester of pregnancy (37-38 weeks of pregnancy)</time_frame>
    <description>Duration of pregnancy (weeks and days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome - birth weight</measure>
    <time_frame>at one time point immediately after childbirth</time_frame>
    <description>Birth weight (in grams)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome - birth length</measure>
    <time_frame>at one time point immediately after childbirth</time_frame>
    <description>Birth length (in cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcome - Apgar score</measure>
    <time_frame>at one time point immediately after childbirth</time_frame>
    <description>Apgar score (in Apgar score scale, a total score of 1 to 10; the higher the score, the better the baby is doing after birth)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>at one time point in the third trimester of pregnancy (37-38 weeks of pregnancy)</time_frame>
    <description>Automatic oscillometric measurement of systolic and diastolic blood pressure (in mmHg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>at one time point in the third trimester of pregnancy (37-38 weeks of pregnancy)</time_frame>
    <description>Automatic oscillometric measurement of heart rate (bpm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Body mass index</measure>
    <time_frame>at one time point in the third trimester of pregnancy (37-38 weeks of pregnancy)</time_frame>
    <description>Measurement of BMI (kg/m2)</description>
  </other_outcome>
  <other_outcome>
    <measure>Body composition</measure>
    <time_frame>at one time point in the third trimester of pregnancy (37-38 weeks of pregnancy)</time_frame>
    <description>Body composition and body fluid status measurement by a four-terminal portable impedance analyzer. Based on the value of skin resistance (Ohm) empirically derived formulas (the original manufacturer's software) will be used to calculate the estimated Fat Free Mass (FFM kg) and Fat (Fat Mass kg).</description>
  </other_outcome>
  <other_outcome>
    <measure>Body fluid status</measure>
    <time_frame>at one time point in the third trimester of pregnancy (37-38 weeks of pregnancy)</time_frame>
    <description>Body fluid status measurement by a four-terminal portable impedance analyzer. Based on the value of skin resistance (Ohm) empirically derived formulas (the original manufacturer's software) will be used to calculate the estimated Total Body Water (TBW L), Extracellular Water (ECW L), Intracellular Water (ICW L), Plasma Fluid (PF L) and Interstitial Fluid (IF L).</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Salt; Excess</condition>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>Low-salt (LS) group</arm_group_label>
    <description>intake of &lt; 5 g of salt per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal-salt (NS) group</arm_group_label>
    <description>intake of 5 - 7.5 g of salt per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-salt (HS) group</arm_group_label>
    <description>intake of 7.5 - 10 g of salt per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Very high-salt (VHS) group</arm_group_label>
    <description>intake of &gt; 10 g of salt per day</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, placental tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        healthy pregnant women in the third trimester of pregnancy (37-38 weeks of pregnancy)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy pregnant women in the third trimester of pregnancy (37-38 weeks of pregnancy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  prenatal hypertension&#xD;
&#xD;
          -  thrombophilia&#xD;
&#xD;
          -  low molecular weight heparin use&#xD;
&#xD;
          -  coronary heart disease&#xD;
&#xD;
          -  preconception diabetes&#xD;
&#xD;
          -  gestational diabetes&#xD;
&#xD;
          -  renal impairment&#xD;
&#xD;
          -  cerebrovascular and peripheral artery disease&#xD;
&#xD;
          -  any other preconception disease that could affect vascular and endothelial function&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ines Drenjancevic, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine Josip Juraj Strossmayer University of Osijek</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martina Vulin, MD</last_name>
    <phone>+38531512300</phone>
    <email>martina.vulin@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osijek University Hospital</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Vulin, MD</last_name>
      <phone>+385 31 512 300</phone>
      <email>martina.vulin@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Josip Juraj Strossmayer University of Osijek</investigator_affiliation>
    <investigator_full_name>Ines Drenjancevic</investigator_full_name>
    <investigator_title>Head of Department of Physiology and Immunology Faculty of Medicine Osijek</investigator_title>
  </responsible_party>
  <keyword>salt intake</keyword>
  <keyword>microcirculation</keyword>
  <keyword>macrocirculation</keyword>
  <keyword>endothelium</keyword>
  <keyword>uteroplacental function</keyword>
  <keyword>pregnancy</keyword>
  <keyword>oxidative stress</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

